Genocea Biosciences
Cambridge, US · Delaware corporation · 5 known investors
Uses a T-cell antigen discovery platform to develop vaccines for oncology and infectious disease.
Biotech
Founders & leadership
NS
Narinder SinghExecutive
DM
Derek MeisnerExecutive
MA
Michael AlfieriExecutive
JF
Jessica FlechtnerExecutive
GA
Girish AakaluExecutive
TD
Thomas DavisExecutive
WC
William ClarkExecutive
Board
KB
AB
RC
Ronald CooperBoard director
MH
Michael HigginsBoard director
GS
George SiberBoard director
Investors · 5
Reported raises · per SEC filings
Form D private placements$87.6M disclosed across 2 rounds · 2019–2020
▶$75.5MraisedAug 2020 · 18 investors · BiotechnologyRule 506(b)
▶$75.5MraisedAug 2020 · 18 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- JESSICA FLECHTNERExecutive Officer
- THOMAS DAVISExecutive Officer
- KATRINE BOSLEYDirector
- MICHAEL HIGGINSDirector
- ALI BEHBAHANIDirector
- GEORGE SIBERDirector
- GIRISH AAKALUExecutive Officer
- DIANTHA DUVALLExecutive Officer
- GISELA SCHWABDirector
- KENNETH BATEDirector
- WILLIAM CLARKExecutive Officer
- HOWARD MAYERDirector
- RONALD COOPERDirector
- Offering amount
- $79.9M
- Amount sold
- $75.5M
- Sales commissions
- $4.8M
- Placement agents
- STIFEL, NICOLAUS & COMPANY, INCORPORATED
- First sale
- Jul 2020
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$12.1MraisedFeb 2019 · 9 investors · BiotechnologyRule 506(b)
▶$12.1MraisedFeb 2019 · 9 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Narinder SinghExecutive Officer
- Derek MeisnerExecutive Officer
- Michael AlfieriExecutive Officer
- Katrine BosleyDirector
- Jessica FlechtnerExecutive Officer
- Ali BehbahaniDirector
- Girish AakaluExecutive Officer
- Ronald CooperDirector
- Michael HigginsDirector
- Thomas DavisExecutive Officer
- George SiberDirector
- William ClarkExecutive Officer
- Kenneth BateDirector
- Pamela CarrollExecutive Officer
- Howard MayerDirector
- Offering amount
- $15M
- Amount sold
- $12.1M
- Sales commissions
- $750K
- First sale
- Feb 2019
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Frequently asked questions
- What does Genocea Biosciences do?
- Uses a T-cell antigen discovery platform to develop vaccines for oncology and infectious disease.
- Who are Genocea Biosciences's investors?
- Genocea Biosciences's investors include Cycad Group LLC, Lux Capital, MC Healthcare Ventures, Advent Life Sciences, New Enterprise Associates (NEA).
- How much funding has Genocea Biosciences raised?
- Genocea Biosciences has disclosed $87.6M raised across 2 rounds.
- Where is Genocea Biosciences headquartered?
- Genocea Biosciences is headquartered in Cambridge, US.